39 56

Cited 0 times in

정신분열병에 대한 리스페리돈의 효과 및 안정성(장기투여연구)

Other Titles
 Efficacy and Safety Profile of Risperidone in Schizophrenia:Long-term Follow-up Study 
Authors
 이민수  ;  김용구  ;  강병조  ;  김광수  ;  김영훈  ;  김희철  ;  나 철  ;  노승호  ;  백인호  ;  연병길  ;  오병훈  ;  윤도준  ;  윤진상  ;  이종범  ;  이 철  ;  전태연  ;  정인과  ;  정인원  ;  지익성  ;  채정호  ;  한상익  ;  서광윤 
Citation
 Journal of the Korean Neuropsychiatric Association (신경정신의학), Vol.38(1) : 116-127, 1999 
Journal Title
 Journal of the Korean Neuropsychiatric Association (신경정신의학) 
ISSN
 1015-4817 
Issue Date
1999
Keywords
Schizophrenia ; Risperidone ; Long-term efficacy ; Safety
Abstract
Objectives:The purpose of this study was to evaluate the long-term efficacy and safety of risperidone in the treatment of Korean schizophrenic patients. Method:This multicenter open label study included 116 schizophrenic patients drawn from 19 university hospitals. After a wash-out period of 1 week, the patients were treated with risperidone for 56 weeks and evaluated at 8 points:at baseline, and the 8th, 16th, 24th, 32nd, 40th, 48th, 56th weeks of treatment. The dose was started at 2mg of risperidone on day 1, and increased to 4mg on day 2, and 6mg on day 3–7 and adjusted to a maximum of 16mg/day according to the individual’s clinical response. The psychiatric and neurological status of the patients was assessed by PANSS, CGI, and ESRS scales. Results:Eighty-seven(75%) of 116 patients completed the 56-week trial of risperidone. Clinical improvement(as defined by a 20% of reduction in total PANSS score at end point) was shown by 92.0% of the patients. The mean dose of risperidone was 5.0mg/day in the 56 week follow-up. PANSS total scores showed significant improvements between consecutive two points at baseline, 8th, 16th, 24th, 32nd, and 48th week of treatment. CGI scores showed significant reductions between consecutive two points at baseline, 8th, 16th, 24th, and 48th week of treatment. Three PANSS factors(positive, negative, general) showed a significant improvement from the 8th week of treatment, and, after then, remained improved in the rest of the study period. ESRS showed no significant change during the 56 week trial. Laboratory parameters showed no significant changes during the course of treatment. Conclusions:This multicenter long-term open study suggests that risperidone is a antipsychotic drug with long term efficacy and safety in the treatment of schizophrenic patients
Files in This Item:
T199901337.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
Oh, Byong Hoon(오병훈)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/172622
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links